Infinitopes Precision Immunomics, an Oxford-based cancer biotech, raised £12.8M in Seed funding.

The funding round was led by Octopus Ventures, with Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital, and several angel investors participating.

Funds will accelerate the installation of LC-MS/MS mass spectrometer equipment, advancing their proprietary tumour antigen discovery, and AI/machine learning techniques. This will help identify and rank the best targets to treat additional cancers.

CEO Jonathan Kwok highlighted the company's goal to transform cancer care with their precision-targeted, durable cancer vaccines. The lead vaccine candidate, ITOP1, will begin phase I/IIa trials in Q3 2024, aimed at preventing tumour recurrence effectively.